http://www.fpnotebook.com/
Entry Inhibitor
Aka: Entry Inhibitor, Maraviroc, Selzentry
- See Also
- Anti-Retroviral Therapy
- Class
- Anti-retroviral agent
- Entry Inhibitor
- Mechanism
- Blocks HIV to chemokine (CCR5 - R5) receptor binding on CD4 cells
- Since only effective on R5 cells - requires R5 tropism test prior to initiating Maraviroc
- Indications
- Anti-retroviral naive patients
- Anti-retroviral experienced patients
- Adverse Effects
- Well tolerated overall
- Fever
- Upper respiratory symptoms (e.g. cough, Bronchitis)
- Abdominal Pain
- Rash
- Orthostatic Hypotension
- Myalgia
- Hepatotoxicity (may be associated with rash and Eosinophilia)
- Increased Myocardial Infarction risk
- Monitoring
- Requires R5 tropism test prior to initiating Maraviroc
- References
- (2009) Treat Guidel Med Lett 7(78): 11-22
- Reust (2011) Am Fam Physician 83(12): 1443-51